Gilead’s Remdesivir approved by FDA as coronavirus treatment

I also wrote on the huge upside potential of Gilead when they acquired Immunomedics for $21 billion.
The acquisition expands Gilead's portfolio of treatments for various types of cancer.

On 9/10/2020 Oppenheimer Brokerage Boosted Price Target to Outperform from $90.00 ➝ $105.00 per share.

They have a 76.063B MARKET CAP, a beautiful 4.48% DIV YIELD, and a great Net Income of 5.386B, for a Forward P/E Ratio of only 8.87, which is great!

GILD stock was oversold lately and the two different algorithm indicators showed a buy signal on 1 hour respectively 3 hours timeframes.

If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.